Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar V Parikh

Showing results (91-100 of 189) with videos related to

Pageof 19
Sort By:
Journal of Affective Disorders|December 18, 2021
Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study reportYuelee Khoo, Ilya Demchenko, Benicio N Frey, et al.
Journal of Clinical Psychopharmacology|September 3, 2025
Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With DepressionRenee E Albers, Melissa P Dyer, Matthew Kucera, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 27, 2013
Psychosocial interventions for bipolar disorder and coping style modification: similar clinical outcomes, similar mechanisms?Sagar V Parikh, Lisa D Hawke, Ari Zaretsky, et al.
Journal of Affective Disorders|December 8, 2022
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depressionAdrienne Lapidos, Daniela Lopez-Vives, Cortney E Sera, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 4, 2016
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the ElderlyGlenda M MacQueen, Benicio N Frey, Zahinoor Ismail, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 6, 2017
Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression GuidelinesSagar V Parikh, Lena Quilty, Paula Ravitz, et al.
BMC Psychiatry|June 26, 2023
Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe surveySubhara Raveendran, Deepshikha Singh, Mary C Burke, et al.
Journal of Affective Disorders|November 8, 2023
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorderMark J Niciu, Robert C Meisner, Brent R Carr, et al.
The Journal of Clinical Psychiatry|July 17, 2012
A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]Sagar V Parikh, Ari Zaretsky, Serge Beaulieu, et al.
Pharmacopsychiatry|March 2, 2021
Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND ReportEmma Morton, Venkat Bhat, Peter Giacobbe, et al.
Pageof 19

Showing results (91-100 of 189) with videos related to

Sort By:
Pageof 19
Journal of Affective Disorders|December 18, 2021
Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study reportYuelee Khoo, Ilya Demchenko, Benicio N Frey, et al.
Journal of Clinical Psychopharmacology|September 3, 2025
Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With DepressionRenee E Albers, Melissa P Dyer, Matthew Kucera, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 27, 2013
Psychosocial interventions for bipolar disorder and coping style modification: similar clinical outcomes, similar mechanisms?Sagar V Parikh, Lisa D Hawke, Ari Zaretsky, et al.
Journal of Affective Disorders|December 8, 2022
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depressionAdrienne Lapidos, Daniela Lopez-Vives, Cortney E Sera, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 4, 2016
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the ElderlyGlenda M MacQueen, Benicio N Frey, Zahinoor Ismail, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 6, 2017
Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression GuidelinesSagar V Parikh, Lena Quilty, Paula Ravitz, et al.
BMC Psychiatry|June 26, 2023
Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe surveySubhara Raveendran, Deepshikha Singh, Mary C Burke, et al.
Journal of Affective Disorders|November 8, 2023
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorderMark J Niciu, Robert C Meisner, Brent R Carr, et al.
The Journal of Clinical Psychiatry|July 17, 2012
A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]Sagar V Parikh, Ari Zaretsky, Serge Beaulieu, et al.
Pharmacopsychiatry|March 2, 2021
Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND ReportEmma Morton, Venkat Bhat, Peter Giacobbe, et al.
Pageof 19